FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385667113> ?p ?o ?g. }

• W4385667113 endingPage "e258126d" @default.
• W4385667113 startingPage "e258126d" @default.
• W4385667113 abstract "Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: Treatment options that became available over the past two decades, including proteasome inhibitors (PI), immunomodulatory agents (IMiDs) and monoclonal antibodies have significantly improved survival outcomes of patients with multiple myeloma (MM). However, MM is still mostly an incurable disease and patients ultimately progress and become refractory to standard treatments. The increased use of lenalidomide (Len) containing regimens in the frontline treatment setting has led to a higher number of Len-refractory patients in the 2nd-4th lines of therapy (LOT) setting. (Moreau P, Blood Cancer J 2019). However, still limited data is available on baseline characteristics and survival outcomes of real-world European MM patients who have been exposed to Len and become refractory or not. Aims: Describe baseline characteristics and overall-survival (OS) difference between Len-refractory and Len-exposed non-refractory MM patients in 2nd-4th LOT in the real-world setting. Methods: Data from the Registry of Monoclonal Gammopathies (Czech Republic) and the Oncology Information Service registry (Germany) was analyzed in HONEUR, which is a federated data network with patient level data solely stored and governed at local sites with analysis executed centrally, which gives a unique advantage of increasing the sample size for infrequent patient subgroups. The applied method involved an upfront harmonization of the two distinct datasets to a common data model; OMOP CDM v5.3. A centrally developed script was executed to both local data-sources from which aggregate level results were then combined centrally. MM patients exposed to both a PI and Len, in 2nd-4th lines of therapy and with ECOG 0-1, treated between 2015 and 2021 were identified to compare outcomes of Len-exposed, non-refractory versus Len-refractory patients. Refractoriness to Len was defined as disease progression while on Len and/or initiation of subsequent LOT not containing Len within 60 days after stopping the previous Len-containing LOT. Patients fulfilling the eligibility criteria at multiple times in their longitudinal follow-up were included as separate observations with LOT as unit of analysis. Results: A total of 2415 treatment lines were included in the analysis. Of these, 2029 (84.0 %) were from Len-refractory patients. Median follow-up from index date was 22.0 vs 23.5 months for the Len-exposed non-refractory and Len-refractory patients, respectively. Baseline characteristics were generally comparable between the Len-exposed non-refractory and Len-refractory cohorts and will be fully described in the final poster. Median OS for Len -refractory and Len-exposed non-refractory patients was 21.5 [95% CI:19.94; 23.06] vs. 36.6 [95% CI: 31.74; 43.53] months, respectively, with a Hazard Ratio (HR) of 1.89 [95% CI: 1.57; 2.27], p<0.001. (Figure 1a). After adjusting for treatment line, OS was still significantly worse in the Len refractory patients, with risk of death 71% higher compared to the Len-exposed non refractory patients (HR: 1.71 [1.42, 2.06]. The increased risk of death in the Len-refractory vs Len-exposed non-refractory patients was more pronounced in 2nd LOT (HR=1.82 [1.00, 3.27]). (Figure 1b). Summary/Conclusion: Analysis conducted on European patients in the HONEUR federated data network confirms the worse survival prognosis and higher clinical unmet need of MM patients who have become refractory to Len compared to Len-exposed non-refractory patients in the real-world setting. Effective new treatments that can prolong survival for Len-refractory patients are needed.Keywords: Real world data, Multiple myeloma" @default.
• W4385667113 created "2023-08-09" @default.
• W4385667113 creator A5008228831 @default.
• W4385667113 creator A5011620868 @default.
• W4385667113 creator A5014103994 @default.
• W4385667113 creator A5014338847 @default.
• W4385667113 creator A5022237316 @default.
• W4385667113 creator A5030524608 @default.
• W4385667113 creator A5038469895 @default.
• W4385667113 creator A5042429469 @default.
• W4385667113 creator A5049563849 @default.
• W4385667113 creator A5062722992 @default.
• W4385667113 creator A5063380340 @default.
• W4385667113 creator A5072088195 @default.
• W4385667113 creator A5078353739 @default.
• W4385667113 creator A5078665066 @default.
• W4385667113 creator A5080907370 @default.
• W4385667113 creator A5083043172 @default.
• W4385667113 creator A5090197729 @default.
• W4385667113 creator A5090460126 @default.
• W4385667113 creator A5092614024 @default.
• W4385667113 date "2023-08-01" @default.
• W4385667113 modified "2023-10-15" @default.
• W4385667113 title "P944: REAL-WORLD PATIENT CHARACTERISTICS AND SURVIVAL OUTCOMES OF LENALIDOMIDE REFRACTORY VS. LENALIDOMIDE EXPOSED RRMM PATIENTS IN THE HONEUR FEDERATED DATA NETWORK" @default.
• W4385667113 doi "https://doi.org/10.1097/01.hs9.0000970680.25812.6d" @default.
• W4385667113 hasPublicationYear "2023" @default.
• W4385667113 type Work @default.
• W4385667113 citedByCount "0" @default.
• W4385667113 crossrefType "journal-article" @default.
• W4385667113 hasAuthorship W4385667113A5008228831 @default.
• W4385667113 hasAuthorship W4385667113A5011620868 @default.
• W4385667113 hasAuthorship W4385667113A5014103994 @default.
• W4385667113 hasAuthorship W4385667113A5014338847 @default.
• W4385667113 hasAuthorship W4385667113A5022237316 @default.
• W4385667113 hasAuthorship W4385667113A5030524608 @default.
• W4385667113 hasAuthorship W4385667113A5038469895 @default.
• W4385667113 hasAuthorship W4385667113A5042429469 @default.
• W4385667113 hasAuthorship W4385667113A5049563849 @default.
• W4385667113 hasAuthorship W4385667113A5062722992 @default.
• W4385667113 hasAuthorship W4385667113A5063380340 @default.
• W4385667113 hasAuthorship W4385667113A5072088195 @default.
• W4385667113 hasAuthorship W4385667113A5078353739 @default.
• W4385667113 hasAuthorship W4385667113A5078665066 @default.
• W4385667113 hasAuthorship W4385667113A5080907370 @default.
• W4385667113 hasAuthorship W4385667113A5083043172 @default.
• W4385667113 hasAuthorship W4385667113A5090197729 @default.
• W4385667113 hasAuthorship W4385667113A5090460126 @default.
• W4385667113 hasAuthorship W4385667113A5092614024 @default.
• W4385667113 hasBestOaLocation W43856671131 @default.
• W4385667113 hasConcept C121332964 @default.
• W4385667113 hasConcept C126322002 @default.
• W4385667113 hasConcept C142424586 @default.
• W4385667113 hasConcept C143998085 @default.
• W4385667113 hasConcept C2776063141 @default.
• W4385667113 hasConcept C2776364478 @default.
• W4385667113 hasConcept C71924100 @default.
• W4385667113 hasConcept C87355193 @default.
• W4385667113 hasConceptScore W4385667113C121332964 @default.
• W4385667113 hasConceptScore W4385667113C126322002 @default.
• W4385667113 hasConceptScore W4385667113C142424586 @default.
• W4385667113 hasConceptScore W4385667113C143998085 @default.
• W4385667113 hasConceptScore W4385667113C2776063141 @default.
• W4385667113 hasConceptScore W4385667113C2776364478 @default.
• W4385667113 hasConceptScore W4385667113C71924100 @default.
• W4385667113 hasConceptScore W4385667113C87355193 @default.
• W4385667113 hasIssue "S3" @default.
• W4385667113 hasLocation W43856671131 @default.
• W4385667113 hasLocation W43856671132 @default.
• W4385667113 hasOpenAccess W4385667113 @default.
• W4385667113 hasPrimaryLocation W43856671131 @default.
• W4385667113 hasRelatedWork W1988934582 @default.
• W4385667113 hasRelatedWork W2052365909 @default.
• W4385667113 hasRelatedWork W2102372291 @default.
• W4385667113 hasRelatedWork W2111732928 @default.
• W4385667113 hasRelatedWork W2351796763 @default.
• W4385667113 hasRelatedWork W2531713994 @default.
• W4385667113 hasRelatedWork W3031374739 @default.
• W4385667113 hasRelatedWork W3126730168 @default.
• W4385667113 hasRelatedWork W3217566318 @default.
• W4385667113 hasRelatedWork W4297237848 @default.
• W4385667113 hasVolume "7" @default.
• W4385667113 isParatext "false" @default.
• W4385667113 isRetracted "false" @default.
• W4385667113 workType "article" @default.